pancreatic

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA…

2 months ago

Effective 02/07/2025, Interpace Diagnostics to No Longer Offer PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX:…

2 months ago

Theriva Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

December 05, 2024 08:00 ET | Source: Theriva Biologics, Inc. ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics…

3 months ago

Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer

November 26, 2024 03:00 ET | Source: Anocca AB Application to the European Medicines Agency (EMA) covers ANOC-001 as the…

4 months ago